Correlation Between TRAb and Early Onset Hypothyroidism After ¹³¹I Treatment for Gravesʼ Disease

Abstract

The aim of the study was to explore the clinical features related to early hypothyroidism and the relationship between the changes of thyrotropin receptor antibodies (TRAb) and early hypothyroidism in the course of ¹³¹I treatment for Graves’ disease. This study was a retrospective observation, including 226 patients who received the first ¹³¹I treatment. The general information and laboratory tests were collected before and after ¹³¹I treatment, and the laboratory data affecting the difference in disease outcome were analyzed. According to the changes of antibodies in the third month, whether the changes of antibodies were involved in the occurrence of early-onset hypothyroidism was analyzed. Early onset hypothyroidism occurred in 165 of 226 patients, and the results showed that the incidence of early hypothyroidism was higher in patients with low baseline TRAb level (p=0.03) and increased TRAb after treatment (p=0.007). Both baseline TRAb levels (p<0.001) and the 24-hour iodine uptake rate (p=0.004) are significant factors influencing the changes in TRAb. The likelihood of a rise in TRAb was higher when the baseline TRAb was less than 18.55 U/l and the 24-hour iodine uptake level exceeded 63.61%. Low baseline and elevated post-treatment levels of TRAb were significantly associated with early-onset hypothyroidism after ¹³¹I treatment. Monitoring this index during RAI treatment is helpful in identifying early-onset hypothyroidism and mastering the clinical outcome and prognosis of Graves’ disease.

Keywords

early onset hypothyroidism - ¹³¹I treatment - thyrotropin receptor antibody - Gravesʼ disease - retrospective observation

Publication History

Received: 29 November 2023

Accepted after revision: 15 February 2024

Article published online:
04 April 2024

• References

• 1 Lantz M, Planck T, Asman P. et al. Increased TRAb and/or low anti-TPO titers at diagnosis of Graves' disease are associated with an increased risk of developing ophthalmopathy after onset. Exp Clin Endocrinol Diabetes 2014; 122: 113-117
• 2 Hargreaves CE, Grasso M, Hampe CS. et al. Yersinia enterocolitica provides the link between thyroid-stimulating antibodies and their germline counterparts in Graves' disease. J Immunol 2013; 190: 5373-5381
• 3 Seib CD, Chen J, Iagaru A. Shifting trends and informed decision-making in the management of Graves’ disease. Thyroid 2020; 3: 351-354
• 4 Gibb FW, Zammitt NN, Beckett GJ. et al. Predictors of treatment failure, incipient hypothyroidism, and weight gain following radioiodine therapy for Graves' thyrotoxicosis. J Endocrinol Invest 2013; 36: 764-769
• 5 Allahabadia A, Daykin J, Holder RL. et al. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab 2000; 85: 1038-1042
• 6 Sabri O, Zimny M, Schulz G. et al. Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication. J Clin Endocrinol Metab 1999; 84: 1229-1233
• 7 Moura-Neto A, Mosci C, Santos AO. et al. Predictive factors of failure in a fixed 15 mCi ¹³¹I-iodide therapy for Graves' disease. Clin Nucl Med 2012; 37: 550-554
• 8 Murakami Y, Takamatsu J, Sakane S. et al. Changes in thyroid volume in response to radioactive iodine for Graves' hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome. J Clin Endocrinol Metab 1996; 81: 3257-3260
• 9 Walter MA, Christ-Crain M, Eckard B. et al. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome. Eur J Clin Invest 2004; 34: 365-370
• 10 Zantut-Wittmann DE, Ramos CD, Santos AO. et al. High pre-therapy (99mTc) pertechnetate thyroid uptake, thyroid size, and thyrostatic drugs: predictive factors of failure in (¹³¹I) iodide therapy in Graves' disease. Nucl Med Commun 2005; 26: 957-963
• 11 Boelaert K, Syed AA, Manji N. et al. Prediction of cure and risk of hypothyroidism in patients receiving ¹³¹I for hyperthyroidism. Clin Endocrinol (Oxf) 2009; 70: 129-138
• 12 Liu M, Jing D, Hu J. et al. Predictive factors of outcomes in personalized radioactive iodine (¹³¹I) treatment for Graves' disease. Am J Med Sci 2014; 348: 288-293
• 13 Ross DS, Burch HB, Cooper DS. et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. J Thyroid 2016; 26: 1343-1421
• 14 Chen DY, Schneider PF, Zhang XS. et al. Striving for euthyroidism in radioiodine therapy of Graves' disease: a 12-year prospective, randomized, open-label blinded endpoint study. J Thyroid 2011; 21: 647-654
• 15 Sundaresh V, Brito JP, Wang Z. et al. Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2013; 98: 3671-3677
• 16 Rooij A, Vandenbroucke JP, Smit JW. et al. Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis. Eur J Endocrinol 2009; 161: 771-777
• 17 Bojarska-Szmygin A, Janicki K, Pietura R. et al Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow's disease. J Ann Univ Mariae Curie Sklodowska Med 2003; 58: 248-253
• 18 Fangdu Li, Jimin Yuan, Zhongjia Wei. et al. Changes of apoptosis molecules in serum of patients with Graves' disease treated with ¹³¹I and their correlation. J Marker Immunoassay Clin 2005; 208: 208-210
• 19 Jones BM, Kwok CC, Kung AW. Effect of radioactive iodine therapy on cytokine production in Gravesʼ disease: transient increases in interleukin-4 IL-4, IL-6, IL-10, and tumor necrosis factor-alpha, with longer term increases in interferon-gamma production. J Clin Endocrinol Metab 1999; 84: 4106-4110
• 20 Panganiban RA, Mungunsukh O, Day RM. X-irradiation induces ER stress, apoptosis, and senescence in pulmonary artery endothelial cells. Int J Radiat Biol 2013; 89: 656-667
• 21 Wen G, Ringseis R, Eder K. Endoplasmic reticulum stress inhibits expression of genes involved in thyroid hormone synthesis and their key transcriptional regulators in FRTL-5 thyrocytes. Plos One 2017; 12: 61-78